

Product Licence Number	Company Name	Product Name	Active Ingredients	Indications	Date of Authorisation
08215/0009 (continued)	Kent Pharmaceuticals Limited			tissue infections should always be carried out in conjunction with any necessary indicated surgical procedures. Dermatological infections: Acne vulgaris and acne conglobata. As it is one of the tetracycline group of antibiotics, it may be expected to be useful in the treatment of infections which respond to other tetracyclines such as: Gastro-intestinal infections: Caused by susceptible strains of such organisms as shigella species, Salmonella species, Entamoeba histolytica and enteropathogenic E.Coli. Ophthalmic infections: Caused by susceptible strains of staphylococci, gonococci and Haemophilus influenzae. Doxycycline is indicated for the treatment of inclusion conjunctivitis either alone or in combination with topical agents. It is also suitable in the treatment of trachoma. However the infectious agent is not eliminated on all occasions, as tested by immunofluorescence techniques. Miscellaneous: Trigonitis and Prostatitis caused by Proteus species. Psittacosis, Certain other infections caused by susceptible strains of Bacterioides species, Listeria species, Rickettsia species, Yersinia species, Brucella species (in combination with streptomycin) and Bordetella pertussis, Calymmato-bacterium granulomatis, Spirochaetes (treponema species), Bacillus anthracis, Neisseria meningitis and Clostridium welchii. It may be a useful adjunct to amoebicides in the treatment of acute intestinal amoebiasis.	
08747/0236	Chemilines Limited	Sumatriptan 6 mg Injection Imigran Injection	Sumatriptan 6.000 mg	Prescription Only Medicine 1. The acute relief of migraine attacks. 2. The acute treatment of cluster headaches.	8th March, 1999
08800/0018	Chiron BV	Proleukin 9 MIU s.c.	Aldesleukin 9.000 miu	Prescription Only Medicine Treatment of metastatic renal cell carcinoma. Risk factors associated with decreased response rates and median survival are: - A performance status of ECOG 1 or greater. - More than one organ with metastatic disease sites. - A period of <24 months between initial diagnosis of primary tumour and the date the patient is evaluated for Proleukin® treatment. Response rates and median survival decrease with the number of risk factors present. Patients positive for all three risk factors should not be treated with Proleukin®.	22nd December, 1998
08800/0019	Chiron BV	Proleukin 18 MIU s.c.	Aldesleukin 18.000 miu	Prescription Only Medicine Same as in PL 08800/0018	22nd December, 1998
10256/0376	Stephar (UK) Limited	Serevent Inhaler	Salmeterol Xinafoate 36.300 mcg	Prescription Only Medicine Reversible airways obstruction.	1st March, 1999
10256/0378	Stephar (UK) Limited	Ikorel 10 mg Tablets	Nicorandil 10.000 mg	Prescription Only Medicine Prevention and treatment of angina pectoris.	1st March, 1999
10256/0379	Stephar (UK) Limited	Ikorel 20 mg Tablets	Nicorandil 20.000 mg	Prescription Only Medicine Same as in PL 10256/0378	1st March, 1999
10256/0382	Stephar (UK) Limited	Cytotec Tablets	Misoprostol 200.000 mcg	Prescription Only Medicine 1. Healing of duodenal and gastric ulcers. 2. The prophylaxis of NSAID-induced ulcers.	11th March, 1999
10256/0383	Stephar (UK) Limited	Coversyl 4 mg Tablets	Perindopril Tert-Butylamine 4.000 mg	Prescription Only Medicine Hypertension and heart failure.	8th March, 1999
10256/0384	Stephar (UK) Limited	Diflucan 50 mg Capsules	Fluconazole 50.000 mg	Prescription Only Medicine The treatment of genital and vaginal candidiasis and candidal balanitis.	12th March, 1999
10256/0391	Stephar (UK) Limited	Omeprazole 10 mg Capsules	Omeprazole 10.000 mg	Prescription Only Medicine The treatment of gastro intestinal diseases requiring a reduction in acid secretion.	10th March, 1999
10256/0392	Stephar (UK) Limited	Livial 2.5 mg Tablets	Tibolone 2.500 mg	Prescription Only Medicine The treatment of symptoms of oestrogen deficiency states.	9th March, 1999